PMID- 25327352
OWN - NLM
STAT- MEDLINE
DCOM- 20150916
LR  - 20150114
IS  - 1365-3148 (Electronic)
IS  - 0958-7578 (Linking)
VI  - 24
IP  - 6
DP  - 2014 Dec
TI  - Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible 
      platelet transfusions in refractory patients.
PG  - 406-10
LID - 10.1111/tme.12157 [doi]
AB  - BACKGROUND: The development of specific antibodies against human leukocyte 
      antigen (HLA) and/or human platelet antigen (HPA) could induce platelet 
      transfusion refractoriness especially in patients receiving multiple platelet 
      transfusions. A retrospective analysis was conducted to evaluate the prevalence 
      of platelet-specific antibodies and the efficacy of crossmatch-compatible 
      platelet transfusions in these recipients. STUDY DESIGN AND METHODS: All enrolled 
      patients were refractory to random single-donor apheresis Platelet (PLT) units. 
      Enzyme-linked immunosorbent assay (ELISA) was used to detect anti-HLA and 
      anti-HPA antibodies in serum. For those patients with antibodies, the PLT 
      crossmatch assays were performed to select the compatible PLTs with a commercial 
      solid-phase adherence kit. RESULTS: A total of 193 patients were included and 
      29.02% of which was HLA and/or HPA antibody-positive. There were no significant 
      differences in antibody-positive rates among AML/CML, ALL/CLL, MDS, SAA and ITP 
      groups, but they are statistically significantly higher than other groups (P = 
      0.0035). Of those antibody-positive patients, there were 41 (73.21%) patients 
      with only HLA antibodies, 11 (19.64%) patients with only HPA antibodies and 4 
      (7.14%) patients with both HLA and HPA antibodies. A total of 43 random PLT units 
      and 88 crossmatch-compatible PLT units were administered. The mean (+/- SD) 
      corrected count increment (CCI) was 8700 (+/- 4500) after crossmatch-compatible 
      unit transfusion, significantly higher than 3600 (+/- 2400) for random PLT units (P 
      < 0.001). CONCLUSIONS: HLA and/or HPA alloimmunisation is an important factor to 
      cause refractoriness to platelet transfusions. Crossmatch-compatible platelet 
      transfusion is an effective method in those patients refractory to random 
      platelet transfusions.
CI  - (c) 2014 British Blood Transfusion Society.
FAU - Jia, Y
AU  - Jia Y
AD  - Department of HLA, Beijing Red Cross Blood Center, Beijing, P. R. China.
FAU - Li, W
AU  - Li W
FAU - Liu, N
AU  - Liu N
FAU - Zhang, K
AU  - Zhang K
FAU - Gong, Z
AU  - Gong Z
FAU - Li, D
AU  - Li D
FAU - Wang, L
AU  - Wang L
FAU - Wang, D
AU  - Wang D
FAU - Jing, Y
AU  - Jing Y
FAU - Wang, J
AU  - Wang J
FAU - Shan, X
AU  - Shan X
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20141019
PL  - England
TA  - Transfus Med
JT  - Transfusion medicine (Oxford, England)
JID - 9301182
RN  - 0 (Antigens, Human Platelet)
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, Human Platelet/*immunology
MH  - *Blood Grouping and Crossmatching
MH  - Female
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Isoantibodies/*blood/immunology
MH  - Male
MH  - Middle Aged
MH  - Platelet Transfusion/*adverse effects
MH  - Prevalence
MH  - Retrospective Studies
OTO - NOTNLM
OT  - platelet transfusion refractoriness
OT  - platelet-specific antibodies
EDAT- 2014/10/21 06:00
MHDA- 2015/09/17 06:00
CRDT- 2014/10/21 06:00
PHST- 2014/03/18 00:00 [received]
PHST- 2014/07/23 00:00 [revised]
PHST- 2014/09/06 00:00 [accepted]
PHST- 2014/10/21 06:00 [entrez]
PHST- 2014/10/21 06:00 [pubmed]
PHST- 2015/09/17 06:00 [medline]
AID - 10.1111/tme.12157 [doi]
PST - ppublish
SO  - Transfus Med. 2014 Dec;24(6):406-10. doi: 10.1111/tme.12157. Epub 2014 Oct 19.